Hemofil-M (human plasma derived coagulation factor VIII) / Takeda - LARVOL DELTA

Takeda to discontinue Hemofil M, Recombinate for hemophilia A (Hemophilia News Today) - "Takeda Pharmaceuticals has decided to discontinue Hemofil M (human antihemophilic factor) and Recombinate (recombinant antihemophilic factor), both of which are approved as replacement therapies to prevent and control bleeding episodes in children and adults with hemophilia A....Hemofil M and Recombinate will be supplied until stocks run out or expire by mid-2026, depending on how many patients are still using them before switching to alternative treatments, according to the company."

Discontinued • Hemophilia A

RESIST NAIVE: Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive (clinicaltrials.gov) - P=N/A; N=0; Withdrawn; Sponsor: City of Hope Medical Center; N=148 ➔ 0; Active, not recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Hematological Disorders • Hemophilia • Rare Diseases

[VIRTUAL] Evaluation of IgG4 ELISA for the Screening of Factor VIII Inhibitors in Hemophilia A (ISTH 2020) - "Checkerboard method for optimization of plasma-derived Factor VIII (HEMOFIL M Baxalta US Inc.], sample dilutions, and Antihuman IgG4-HRP conjugated (Southern Biotechnology Inc.,Al,USA) concentration was performed... IgG4 ELISA is a promising tool for screening for PWHA with inhibitors. Sensitivity may be increased by using an enhancer with secondary antibody for improving the colour development."

Gene Therapies • Hematological Disorders • Hemophilia • Rare Diseases